Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.
Hankil LeeHyeonseok ChoJung Woo HanAh-Young KimSeonyoung ParkMinjun LeeSunghwa ChoDeborah BaikHye-Young KangPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)
Emicizumab prophylaxis is an excellent treatment choice reducing ABR, improving quality of life and reducing costs.
Keyphrases